PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?

J Nucl Med. 2018 May;59(5):747-748. doi: 10.2967/jnumed.118.207993. Epub 2018 Feb 9.

David Taïeb¹, Jean-Marc Foletti², Manuel Bardiès^{3

4}, Palma Rocchi⁵, Rodney J Hicks⁶, Uwe Haberkorn^{7

8}

¹ Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France david.taieb@ap-hm.fr.
² Aix-Marseille University, APHM, IFSTTAR, LBA, Hôpital de la Conception, Chirurgie Maxillo-Faciale, Marseille, France.
³ Inserm, UMR1037, CRCT, Toulouse, France.
⁴ Université Toulouse III-Paul Sabatier, UMR1037, CRCT, Toulouse, France.
⁵ Inserm, UMR1068, CRCM, Aix-Marseille University, Marseille, France.
⁶ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
⁷ Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; and.
⁸ Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.

No abstract available

Publication types